ABVC BioPharma provides updates on ADHD Phase IIb clinical study

ABVC BioPharma announced that 60 subjects had been enrolled and 53 had completed the eight-week study for the Company’s ADHD Phase IIb clinical study. These subjects were enrolled at the University of California San Francisco, UCSF. Medical Center and five Taiwanese medical centers. “At all of our sites, the enrollment of subjects participating in our ADHD Phase IIb study is going as planned,” said ABVC BioPharma Chief Executive Officer Uttam Patil, Ph. D. “To reach an interim analysis, the study requires 69 patients’ data. The remaining nine subjects are scheduled for screening in September. Our clinical trials continue to demonstrate that medicine derived from plants can have significant therapeutic benefits, often with few – if any – side effects when treating serious medical conditions.”